Two head-to-head human trials published within weeks of each other in early 2026 tried to answer the question every NAD+ shopper asks: is NMN or NR the better precursor? They came back with different answers — and one of them quietly undermined the mechanism both supplements have been sold on for a decade. If you've been searching "NMN vs NR" or "NAD+ research 2026," this is the state of play, including what it means in Australia now that the TGA has permitted oral NMN at a dose well below what these trials used.

For background on the molecule itself, see our NAD+ profile.

What is NAD+, and why the precursor argument exists

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide — it sits in every cell you have, shuttling electrons through energy metabolism and acting as a substrate for sirtuins and PARP enzymes involved in DNA repair. Tissue NAD+ appears to decline with age in several models, which is the entire commercial premise behind "NAD+ boosters."

You can't usefully swallow NAD+ itself — the molecule is large, charged and gets broken down before absorption. So the market sells precursors: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and plain nicotinamide (Nam, vitamin B3). Which one works best has been argued largely from cell-culture and rodent data, plus single-arm human studies that can't be compared to each other. 2026 finally produced direct comparisons.

The two 2026 head-to-head trials, and why they disagree

The larger trial: NR and NMN finished level

Published in Nature Metabolism in January 2026, a Nestlé-led randomised, open-label, placebo-controlled study gave 65 healthy adults NR (1,000 mg/day), NMN (1,000 mg/day), nicotinamide (500 mg/day) or placebo for 14 days.

Findings: NR and NMN both raised whole-blood NAD+ substantially — roughly doubling it versus placebo — and the two arms were statistically indistinguishable from one another. Nicotinamide, despite being the cheapest and most widely available of the three, produced only a transient spike in the hours after each dose and did not lift baseline NAD+ at all over 14 days.

That is a clean, adequately powered answer to "NMN vs NR": at matched doses over two weeks, no detectable winner. It is worth noting the trial was industry-led (Nestlé Research), and was open-label rather than blinded.

The smaller trial: where the "NR is 2.3× better" claim came from

The competing number doing the rounds — a 161% rise in blood NAD+ on NR versus 67% on NMN, framed as a 2.3-fold advantage for NR — traces back to a phase I pharmacokinetic study from a University of Bergen–linked group, published in iScience in 2026.

Read the primary paper and the framing changes. It enrolled 12 people total — six healthy volunteers and six people with Parkinson's disease — dosed at 1,200 mg/day. Its stated purpose was mapping how oral precursors move NAD+ in blood and brain, not running a precursor bake-off. Its headline findings were kinetic: blood NAD+ rose slowly and plateaued at about two weeks, cerebral NAD+ became measurable only after four weeks, and levels washed out just as slowly after stopping.

That is a genuinely useful result — it suggests short supplementation studies may stop before brain NAD+ has moved. But a between-precursor comparison in six-person groups is hypothesis-generating at best, it is unreplicated, and the specific percentage comparison has been amplified most enthusiastically by a commercial NR brand. Treat a 12-person phase I trial as weaker evidence than a 65-person randomised trial, not stronger, regardless of which answer you prefer.

The gut-microbe twist that reframes the whole question

The more interesting finding in the Nature Metabolism paper had nothing to do with picking a winner.

Using ex vivo fermentation with human gut microbiota, the authors reported that NR and NMN are largely not absorbed intact into systemic circulation. Instead, gut microbes appear to slowly convert them to nicotinic acid (NA) — a potent NAD+ precursor — which then raises whole-blood NAD+ via the Preiss–Handler pathway. Nicotinamide, by contrast, is absorbed rapidly and feeds the salvage pathway, which fits its sharp-but-transient profile.

If that holds up, several things follow. It would explain why NR and NMN behave so similarly in blood despite different molecular routes into cells. It would make your microbiome a variable in how well you respond. And it would complicate a decade of marketing built on the idea that NR enters cells directly while NMN needs an extra step — because on this model, neither is reaching the bloodstream in the form on the label.

This is one study's mechanistic interpretation, partly from ex vivo work, and it needs independent replication before anyone rewrites the textbook.

Is NMN legal in Australia? The dose gap nobody mentions

Australia's position changed on 10 December 2025, when the TGA added nicotinamide mononucleotide to the Permissible Ingredients Determination. The conditions are tight:

  • Oral only, as an active ingredient
  • Maximum 500 mg/day
  • 12 weeks or less recommended duration
  • Adults only, not in pregnancy or breastfeeding
  • Two-year sponsor market exclusivity, running to 10 December 2027

Nicotinamide riboside chloride has been a permitted ingredient in Australian listed medicines since 2019. NAD+ and NADH themselves remain non-permitted ingredients here — which is why you won't find a listed NAD+ medicine, and why IV NAD+ infusions sit outside the listed-medicine framework entirely, with very little published clinical evidence behind them. Internationally, the FDA reversed its NMN exclusion position in September 2025.

Now the part that matters for reading those two trials: both used 1,000–1,200 mg/day — two to 2.4 times Australia's legal daily cap for a listed NMN medicine. The doses that generated the "NAD+ doubled" headlines are not the doses available in a compliant Australian product. Whether 500 mg/day for 12 weeks produces the same biochemical effect is a reasonable question that neither 2026 trial answers.

What none of this tells you

Both trials measured a biomarker. Neither measured whether anything happened to a person.

That remains the central problem with the NAD+ field: precursors reliably move blood NAD+, and clinical outcomes have been stubbornly harder to shift. A 2026 phase II pilot in older adults with amnestic mild cognitive impairment doubled blood NAD+ on NR and still missed its cognitive, cerebral blood flow and cardiovascular endpoints over 12 weeks. Systematic reviews of NAD+ augmentation for "anti-ageing and wellness" continue to land on the same verdict: clear biological activity, inconclusive clinical benefit.

Long-term safety is also genuinely unsettled. Short-term trials show good tolerability, but the preclinical literature on NAD+ boosting and tumour biology cuts both ways, and no human dataset is long enough or large enough to settle cancer-risk questions. The TGA's 12-week ceiling on NMN is not an accident.

For how NAD+ compares with the other compounds we cover, see the peptides index. We track new trial readouts and TGA decisions as they land — join the free updates list.

FAQ

Is NMN or NR better for raising NAD+?

The largest head-to-head trial to date (65 adults, Nature Metabolism, January 2026) found NR and NMN raised whole-blood NAD+ comparably at 1,000 mg/day over 14 days, with no statistical difference between them. A much smaller 12-person phase I study reported an advantage for NR, but it is unreplicated and was not designed as a comparison trial.

Is NMN legal in Australia?

Yes, since 10 December 2025, when the TGA permitted oral NMN in listed medicines — capped at 500 mg per day, for 12 weeks or less, adults only, with sponsor market exclusivity until December 2027. NAD+ and NADH remain non-permitted ingredients in Australia; nicotinamide riboside has been permitted since 2019.

What is the maximum NMN dose allowed in Australia?

500 mg per day in a listed medicine, taken orally, for a recommended duration of no more than 12 weeks. The 2026 head-to-head trials used 1,000–1,200 mg/day — up to 2.4 times that cap — so their results don't directly describe what a compliant Australian dose does.

Does IV NAD+ work better than oral NMN or NR?

There is very little published clinical evidence for IV NAD+, and NAD+ is not a permitted ingredient in Australian listed medicines. Claims that infusions are superior to oral precursors are not currently supported by controlled human trials.

Sources

This article is independent information, not medical advice. NMN and nicotinamide riboside are permitted ingredients in Australian listed medicines under specific dose and duration conditions; NAD+ and NADH are not permitted ingredients, and no NAD+ product is TGA-approved to treat, prevent or cure any condition. Speak with a qualified health professional before starting any supplement.